Market Place
Sourcing Support
Jaguar Health Reports Positive Phase 3 Results For Crofelemer
01 Oct 2024 //
ACCESSWIRE
Jaguar Health To Explore Crofelemer For Breast And Lung Cancer
05 Aug 2024 //
ACCESSWIRE
Jaguar Health To Report Phase 3 Crofelemer Results On July 23
18 Jul 2024 //
ACCESSWIRE
Jaguar Health To Report Phase 3 OnTarget Trial Results By July 23
12 Jun 2024 //
ACCESSWIRE
Jaguar Health: Positive Crofelemer Trial Results For Functional Diarrhea
28 May 2024 //
ACCESSWIRE
Jaguar MVID, SBS Trial Applications In Europe
09 May 2024 //
ACCESSWIRE
Crofelemer receives FDA conditional approval for chemotherapy-induced diarrhea
06 May 2024 //
ACCESSWIRE
Jaguar Announces Submission of ODD Application for Crofelemer
12 Feb 2024 //
ACCESSWIRE
Dog Study Published in PLOS ONE Shows Results for Use of Jaguar’s Crofelemer
25 Jan 2024 //
ACCESSWIRE
Jaguar Announces FDA Activation of IND Application for Evaluation of Crofelemer
01 Aug 2023 //
ACCESSWIRE
Jaguar Achieves Approximately 75% Enrollment in Pivotal Phase 3 of Crofelemer
21 Feb 2023 //
ACCESSWIRE
Jaguar Health Announces that ODD Application Submitted to FDA for Crofelemer
23 Aug 2022 //
ACCESSWIRE
Jaguar Health Completes Third-party, Investigator-Initiated Study of Crofelemer
01 Feb 2022 //
ACCESSWIRE
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing
23 Dec 2020 //
ACCESSWIRE
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing
23 Dec 2020 //
ACCESSWIRE
RedHill Biopharma Initiates Co-Promotion of HIV/AIDS Anti-Diarrheal Drug Mytesi
30 Jul 2018 //
GLOBENEWSWIRE
RedHill`s Announces U.S. Co-Promotion Agreement with Napo for HIV/AIDS Mytesi®
28 Jun 2018 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.